The global passive transdermal drug delivery market is expected to grow at a CAGR of 8.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic diseases, growing geriatric population, and rising demand for non-invasive treatments. The global passive transdermal drug delivery market is segmented on the basis of type into microfluidics and smart pill technology (SPT). Microfluidics segment accounted for the largest share in 2018 owing to its ability to deliver drugs through small channels with high precision. SPT segment is expected to grow at a higher CAGR during the forecast period due to its ability to deliver drugs through an oral route without any invasive procedures. On the basis of application, the global passive transdermal drug delivery market has been classified into clinic and hospital segments. The hospital segment accounted for a larger share in 2018 owing to its use in hospitals where patients are admitted for long periods of time and require continuous treatment with medications that cannot be taken orally or intravenously due their side effects or other reasons such as allergies or intolerance towards certain drugs.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is driving the growth of the global Passive Transdermal Drug Delivery market.
- Increasing awareness about passive transdermal drug delivery among patients and healthcare professionals is also driving the growth of this market globally.
- The increasing number of R&D activities in this field are also contributing to the growth of this market globally 5.The high cost associated with passive transdermal drug delivery systems is a major restraint for this market.
Industry Growth Insights published a new data on “Passive Transdermal Drug Delivery Market”. The research report is titled “Passive Transdermal Drug Delivery Market research by Types (Microfluidics, Smart Pill Technology (SPT)), By Applications (Clinic, Hospital, Others), By Players/Companies 3M, Actavis, Inc., Bayer AG, Boehringer Ingelheim GmbH, Corium International, Inc., Echo Therapeutics, Inc., GlaxoSmithKline plc, Johnson & Johnson (Janssen Pharmaceuticals Inc.), Mylan N.V., Novartis AG, Noven Pharmaceuticals, Inc., Transdermal Corp.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Passive Transdermal Drug Delivery Market Research Report
By Type
Microfluidics, Smart Pill Technology (SPT)
By Application
Clinic, Hospital, Others
By Companies
3M, Actavis, Inc., Bayer AG, Boehringer Ingelheim GmbH, Corium International, Inc., Echo Therapeutics, Inc., GlaxoSmithKline plc, Johnson & Johnson (Janssen Pharmaceuticals Inc.), Mylan N.V., Novartis AG, Noven Pharmaceuticals, Inc., Transdermal Corp.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Passive Transdermal Drug Delivery Market Report Segments:
The global Passive Transdermal Drug Delivery market is segmented on the basis of:
Types
Microfluidics, Smart Pill Technology (SPT)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 3M
- Actavis, Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Corium International, Inc.
- Echo Therapeutics, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson (Janssen Pharmaceuticals Inc.)
- Mylan N.V.
- Novartis AG
- Noven Pharmaceuticals, Inc.
- Transdermal Corp.
Highlights of The Passive Transdermal Drug Delivery Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Microfluidics
- Smart Pill Technology (SPT)
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Passive Transdermal Drug Delivery Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Passive transdermal drug delivery is a method of delivering drugs through the skin without any user intervention. Drugs are absorbed through the skin and then travel to the body's tissues where they can work their magic. This type of delivery is especially beneficial for medications that need to be taken on a regular basis, as it eliminates some of the hassle associated with taking medication regularly (e.g., having to remember to take pills, swallowing pills whole, etc.).
Some of the key players operating in the passive transdermal drug delivery market are 3M, Actavis, Inc., Bayer AG, Boehringer Ingelheim GmbH, Corium International, Inc., Echo Therapeutics, Inc., GlaxoSmithKline plc, Johnson & Johnson (Janssen Pharmaceuticals Inc.), Mylan N.V., Novartis AG, Noven Pharmaceuticals, Inc., Transdermal Corp..
The passive transdermal drug delivery market is expected to register a CAGR of 8.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Passive Transdermal Drug Delivery Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Passive Transdermal Drug Delivery Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Passive Transdermal Drug Delivery Market - Supply Chain
4.5. Global Passive Transdermal Drug Delivery Market Forecast
4.5.1. Passive Transdermal Drug Delivery Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Passive Transdermal Drug Delivery Market Size (000 Units) and Y-o-Y Growth
4.5.3. Passive Transdermal Drug Delivery Market Absolute $ Opportunity
5. Global Passive Transdermal Drug Delivery Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Passive Transdermal Drug Delivery Market Size and Volume Forecast by Type
5.3.1. Microfluidics
5.3.2. Smart Pill Technology (SPT)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Passive Transdermal Drug Delivery Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Passive Transdermal Drug Delivery Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Passive Transdermal Drug Delivery Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Passive Transdermal Drug Delivery Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Passive Transdermal Drug Delivery Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Passive Transdermal Drug Delivery Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Passive Transdermal Drug Delivery Demand Share Forecast, 2019-2026
9. North America Passive Transdermal Drug Delivery Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Passive Transdermal Drug Delivery Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Passive Transdermal Drug Delivery Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Passive Transdermal Drug Delivery Market Size and Volume Forecast by Type
9.7.1. Microfluidics
9.7.2. Smart Pill Technology (SPT)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Passive Transdermal Drug Delivery Demand Share Forecast, 2019-2026
10. Latin America Passive Transdermal Drug Delivery Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Passive Transdermal Drug Delivery Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Passive Transdermal Drug Delivery Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Passive Transdermal Drug Delivery Market Size and Volume Forecast by Type
10.7.1. Microfluidics
10.7.2. Smart Pill Technology (SPT)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Passive Transdermal Drug Delivery Demand Share Forecast, 2019-2026
11. Europe Passive Transdermal Drug Delivery Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Passive Transdermal Drug Delivery Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Passive Transdermal Drug Delivery Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Passive Transdermal Drug Delivery Market Size and Volume Forecast by Type
11.7.1. Microfluidics
11.7.2. Smart Pill Technology (SPT)
11.8. Basis Point Share (BPS) Analysis by Tpe
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Passive Transdermal Drug Delivery Demand Share, 2019-2026
12. Asia Pacific Passive Transdermal Drug Delivery Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Passive Transdermal Drug Delivery Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Passive Transdermal Drug Delivery Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Passive Transdermal Drug Delivery Market Size and Volume Forecast by Type
12.7.1. Microfluidics
12.7.2. Smart Pill Technology (SPT)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Passive Transdermal Drug Delivery Demand Share, 2019-2026
13. Middle East & Africa Passive Transdermal Drug Delivery Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Passive Transdermal Drug Delivery Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Passive Transdermal Drug Delivery Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Passive Transdermal Drug Delivery Market Size and Volume Forecast by Type
13.7.1. Microfluidics
13.7.2. Smart Pill Technology (SPT)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Passive Transdermal Drug Delivery Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Passive Transdermal Drug Delivery Market: Market Share Analysis
14.2. Passive Transdermal Drug Delivery Distributors and Customers
14.3. Passive Transdermal Drug Delivery Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. 3M
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Actavis, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer AG
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Boehringer Ingelheim GmbH
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Corium International, Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Echo Therapeutics, Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GlaxoSmithKline plc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Johnson & Johnson (Janssen Pharmaceuticals Inc.)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Mylan N.V.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis AG
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Noven Pharmaceuticals, Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Transdermal Corp.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook